# Bristol-Myers Squibb (BMY) earnings: $7.05B in 2025

URL: https://funkfolio.com/stock/BMY/earnings

> Bristol-Myers Squibb (BMY) earnings were $7.05B in fiscal 2025. Over ten fiscal years it grew 16.2% a year. Year-by-year chart and table.

---

## Bristol-Myers Squibb (BMY) earnings

**Earnings (net income) · fiscal 2025:** $7.05B year ended Dec 31, 2025

Bristol-Myers Squibb (BMY) reported net income of $7.05B in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$8.95B. Figures as of 18 Nov 2026, 04:45 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Earnings (net income), fiscal 2025:** $7.05B
- **Growth, 10 years:** +16.2% a year
- **Highest on record:** $10.61B fiscal 2009
- **Lowest on record:** -$9.02B fiscal 2020
- **Fiscal years on record:** 19 2007–2025

Figures as of 18 Nov 2026, 04:45 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Bristol-Myers Squibb earnings, in more detail

Over the ten fiscal years to 2025 net income grew at a compound 16.2% a year. Across the 19 fiscal years on record (2007–2025), the highest was $10.61B in fiscal 2009 and the lowest -$9.02B in fiscal 2020.

### Earnings (net income) by fiscal year

### Bristol-Myers Squibb earnings, year by year

Bristol-Myers Squibb (BMY) earnings by fiscal year

| Fiscal year | Earnings (net income) | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | $7.05B | — | Dec 31, 2025 |
| 2024 | -$8.95B | 211.5% down | Dec 31, 2024 |
| 2023 | $8.03B | 26.8% up | Dec 31, 2023 |
| 2022 | $6.33B | 9.5% down | Dec 31, 2022 |
| 2021 | $6.99B | — | Dec 31, 2021 |
| 2020 | -$9.02B | 362.1% down | Dec 31, 2020 |
| 2019 | $3.44B | 30.1% down | Dec 31, 2019 |
| 2018 | $4.92B | 388.6% up | Dec 31, 2018 |
| 2017 | $1.01B | 77.4% down | Dec 31, 2017 |
| 2016 | $4.46B | 184.8% up | Dec 31, 2016 |
| 2015 | $1.57B | 21.9% down | Dec 31, 2015 |
| 2014 | $2.00B | 21.8% down | Dec 31, 2014 |
| 2013 | $2.56B | 30.8% up | Dec 31, 2013 |
| 2012 | $1.96B | 47.2% down | Dec 31, 2012 |
| 2011 | $3.71B | 19.6% up | Dec 31, 2011 |
| 2010 | $3.10B | 70.8% down | Dec 31, 2010 |
| 2009 | $10.61B | 102.2% up | Dec 31, 2009 |
| 2008 | $5.25B | 142.4% up | Dec 31, 2008 |
| 2007 | $2.17B | — | Dec 31, 2007 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

### How to read it

Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.

### Earnings (net income) at health care companies of similar size

Earnings (net income) of Bristol-Myers Squibb and comparable companies

| Company | Earnings (net income) | Fiscal year |
| --- | --- | --- |
| [Vertex Pharmaceuticals VRTX](https://funkfolio.com/stock/VRTX/earnings) | $3.95B | 2025 |
| [Medtronic MDT](https://funkfolio.com/stock/MDT/earnings) | $4.80B | 2026 |
| Bristol-Myers Squibb BMY | $7.05B | 2025 |
| [Stryker SYK](https://funkfolio.com/stock/SYK/earnings) | $3.25B | 2025 |
| [McKesson MCK](https://funkfolio.com/stock/MCK/earnings) | $4.76B | 2026 |
| [Sanofi SNY](https://funkfolio.com/stock/SNY/earnings) | €7.81B | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Bristol-Myers Squibb, figure by figure

- [Bristol-Myers Squibb market cap](https://funkfolio.com/stock/BMY/market-cap)
- [Bristol-Myers Squibb revenue](https://funkfolio.com/stock/BMY/revenue)
- [Bristol-Myers Squibb earnings per share (EPS)](https://funkfolio.com/stock/BMY/eps)
- [Bristol-Myers Squibb P/E ratio](https://funkfolio.com/stock/BMY/pe-ratio)
- [Bristol-Myers Squibb P/S ratio](https://funkfolio.com/stock/BMY/ps-ratio)
- [Bristol-Myers Squibb P/B ratio](https://funkfolio.com/stock/BMY/pb-ratio)
- [Bristol-Myers Squibb free cash flow](https://funkfolio.com/stock/BMY/free-cash-flow)
- [Bristol-Myers Squibb operating margin](https://funkfolio.com/stock/BMY/operating-margin)
- [Bristol-Myers Squibb dividend](https://funkfolio.com/stock/BMY/dividend)
- [Bristol-Myers Squibb shares outstanding](https://funkfolio.com/stock/BMY/shares-outstanding)
- [Bristol-Myers Squibb total debt](https://funkfolio.com/stock/BMY/total-debt)
- [Bristol-Myers Squibb cash on hand](https://funkfolio.com/stock/BMY/cash)
- [Bristol-Myers Squibb total assets](https://funkfolio.com/stock/BMY/total-assets)
- [Bristol-Myers Squibb return on equity (ROE)](https://funkfolio.com/stock/BMY/roe)
- [Bristol-Myers Squibb return on invested capital (ROIC)](https://funkfolio.com/stock/BMY/roic)

[Bristol-Myers Squibb (BMY) overview: price, valuation and scorecard](https://funkfolio.com/stock/BMY) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Bristol-Myers Squibb earnings: questions and answers

**What is Bristol-Myers Squibb's net income?**

Bristol-Myers Squibb (BMY) reported net income of $7.05B in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$8.95B.

**What is the growth rate of Bristol-Myers Squibb's net income?**

Over the ten fiscal years to 2025 net income grew at a compound 16.2% a year.

**What are the highest and lowest net income figures on record for Bristol-Myers Squibb?**

Across the 19 fiscal years on record (2007–2025), the highest was $10.61B in fiscal 2009 and the lowest -$9.02B in fiscal 2020.

**How is Bristol-Myers Squibb's net income calculated?**

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

Fiscal years are named for the calendar year they end in.

### Learn: earnings

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Revenue vs earnings vs free cash flow: what each tells you](https://funkfolio.com/learn/stocks/revenue-earnings-free-cash-flow)

  Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Bristol-Myers Squibb (BMY) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/BMY/earnings

Underlying data: the company's filings with the SEC and Yahoo Finance.
